aspirin has been researched along with thrombin receptor peptide (42-55) in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Modi, NB; Novotny, W; Reimann, JD | 1 |
| Gebauer, MU; Haeberli, A; Julmy, F; Meyer, BJ; Moshfegh, K; Redondo, M; Wuillemin, WA | 1 |
2 trial(s) available for aspirin and thrombin receptor peptide (42-55)
| Article | Year |
|---|---|
Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered GP IIb/IIIa antagonist, following coadministration of aspirin and heparin.
Topics: Adenosine Diphosphate; Administration, Oral; Adult; Anticoagulants; Area Under Curve; Aspirin; Bleeding Time; Cross-Over Studies; Drug Interactions; Female; Heparin; Humans; Male; Middle Aged; Oximes; Partial Thromboplastin Time; Peptide Fragments; Piperidines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prodrugs; Prothrombin Time; Receptors, Thrombin | 2000 |
Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy.
Topics: Adenosine Diphosphate; Adult; Aged; Antigens, CD; Aspirin; Blood; Clopidogrel; Collagen; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dual Specificity Phosphatase 2; Humans; Middle Aged; Myocardial Infarction; P-Selectin; Peptide Fragments; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Prospective Studies; Protein Phosphatase 2; Protein Tyrosine Phosphatases; Tetraspanin 30; Ticlopidine | 2000 |